HOTH Insider Trading Activities: CEO Shows Confidence with Recent Stock Purchase Amidst Steady Figures
In the latest developments concerning insider activities at Hoth Therapeutics, Inc. (HOTH), it has come to light that there has been a singular insider trading event over the past year. The event, a purchase made by the company's Chief Executive Officer Robb Knie, involves a transaction of 25,000 shares at a price of $0.67 per share, totaling $16,750. This purchase, dated August 16, 2024, highlights a moment of confidence from one of the key figures within the company.
Despite this singular purchase being the only transaction within the past twelve months, it is noteworthy to consider the broader context of insider trading activity across the history of HOTH. Over time, there have been a total of 11 insider trading transactions at HOTH, although recent months have shown little to no additional activity in terms of purchases or sales. Specifically, no insider purchases or sales have been recorded in the past six months.
When diving into the insider ownership landscape, the total insider shares held currently stand at 63,860. However, the calculated percentage of net shares purchased or sold has been consistently unreported, indicating a stable position among insiders without significant fluctuations.
A look at the major holders of HOTH indicates that insiders collectively hold a modest 0.925% of company shares. Institutions also maintain a small stake, holding 5.3% of the company's shares, reflecting a relatively low level of institutional endorsement.
Notable institutional stakeholders include Geode Capital Management, LLC, with a 0.74% holding, and Citadel Advisors LLC, holding 0.62%. Other significant players such as Vanguard Group Inc. and Integrated Wealth Concepts LLC represent the minor yet diverse ownership spectrum characterizing HOTH's market position.
In terms of mutual fund interest, holders such as the Vanguard Extended Market Index Fund and Fidelity's various index offerings retain fractional holdings, reflecting a consistent, albeit limited, engagement from mutual fund entities.
In conclusion, while Robb Knie's recent purchase may signal his belief in HOTH's potential, overall insider and institutional engagements reflect a stage of steadiness within the company, without significant insider trading maneuvers shaping market perceptions. Investors and analysts will be closely watching any future insider activity as a barometer for internal confidence and potential changes in company valuation.
CEO's Bold Stock Purchase Highlights Confidence in Steady HOTH Landscape Amid Minimal Insider Activity
Key Points
- Hoth Therapeutics, Inc. (HOTH) has experienced a singular insider trading event in the past year, with CEO Robb Knie purchasing 25,000 shares at $0.67 each on August 16, 2024, indicating his confidence in the company's prospects.
- Historically, HOTH has seen 11 insider transactions, but recent months show no additional trading activity, with insiders holding 63,860 shares, representing 0.925% of company shares.
- Institutional stakeholders maintain a modest presence with 5.3% of shares, including notable entities like Geode Capital and Citadel Advisors, while mutual fund interest remains consistent yet limited.
Cicada Financial Research Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Cicada Financial Research as a whole. Cicada Financial Research is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysis is generated using artificial intelligence and machine learning technologies to process market data and identify patterns. While we strive for accuracy, AI-generated analysis should be considered one of many factors in investment decision-making.
Copy link
Email